ZLDAF (Zelira Therapeutics) Net Interest Margin (Bank Only) %


ZLDAF Zelira Therapeutics Ltd ZLDAF
10 GF Score
Price $0.35
GF Value $0.08
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

ZLDAF
10GF Score
Zelira Therapeutics Ltd ZLDAF
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of $0.35 is trading 337.5% above its estimated GF Value™ of $0.08. GuruFocus considers Zelira Therapeutics to be Significantly Overvalued.

Key valuation signals for ZLDAF:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $0.08 vs. price of $0.35 (337.5% above fair value)
  • GF Score™: 10/100 with 7 warning signs

No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
10GF Score

Get the complete analysis for ZLDAF

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price
$0.08
GF Value